Articles On Orthocell (ASX:OCC)
Title | Source | Codes | Date |
---|---|---|---|
Crucible: Dr Boreham’s A-To-Z of 2024 biotech
From artificial intelligence (A.I) to zygotes, the biotech sector this year delivered the A to Z of excitement, intrigue, occasional disappointment and downright disaster. His virtual stethoscope on hand, Dr Boreham was on duty to diagnose... |
Stockhead | OCC | 6 days ago |
Orthocell marks first sales of nerve repair product Remplir in key market of Singapore
WA biotech Orthocell has started selling its nerve repair product in Singapore, two months after the company received regulatory approval in the country. |
The West | OCC | 1 week ago |
ASX Market Close: Index dives to three week low | December 12, 2024
The ASX200 closed down 0.28% at 8,330 points – finishing the session at a three-week low. Jobs data today surprised analysts, with unemployment falling to 3.9%. Now the odds of an early interest rate cut have lengthened, and the Aussie d... |
themarketonline.com.au | OCC | 1 week ago |
ASX Poised for Gains Amid Nasdaq Surge and Global Market Strength
Key Highlights: Strong Global Market Performance: US and European markets show robust growth, with the Nasdaq hitting a new all-time high. The S&P 500 and European aerospace stocks also saw notable gains, setting a positive tone fo... |
Kalkine Media | OCC | 1 week ago |
Surgical strike: Orthocell’s Remplir breaks into Singapore early
Orthocell (ASX:OCC) has achieved first sales of its peripheral nerve repair product Remplir in Singapore. This marks an early milestone ahead of a previously planned launch in the first quarter of 2025. Remplir is made from a collagen-based... |
ShareCafe | OCC | 1 week ago |
Chris Judd’s Talk Ya Book: Orthocell building on ‘enormous potential’ with steady growth – and US push to come
On Chris Judd’s Talk Ya Book today, the AFL legend sat down with Orthocell Limited (ASX:OCC) chairman John Van Der Wielen to talk about the “overnight success” of the ASX-listed biotech company and its bright future. “We wanted to start... |
themarketonline.com.au | OCC | 2 weeks ago |
ASX November Health Winners: Paradigm, Imricor lead sector as momentum returns
The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX Paradigm Biopharmaceuticals rose 151% in Novembe... |
Stockhead | OCC | 2 weeks ago |
Closing Bell: ASX slides from record high; expert says December pullback may encourage buying
ASX loses momentum after near-record high Tech stocks lead, but CSL falls; retail sales rise 0.6% in October Northern Star to buy De Grey for $5 billion The ASX has lost some of its early momentum today, pulling back from a record high... |
Stockhead | OCC | 3 weeks ago |
Orthocell spikes 7% after clearing huge US hurdle for its nerve repair product
Orthocell (ASX:OCC), has risen more than 7% today after clearing the latest hurdle to distributing its nerve repair product in the U.S. The stock’s bull run over the last two months has seen its share price more than double as investors eye... |
themarketonline.com.au | OCC | 3 weeks ago |
Break it Down: Orthocell’s pivotal path into US healthcare market
Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Sarah Hughan tells all on Orthocell’s (ASX:OCC) nerve repair product deemed safe and effective for use in the surgical repair of per... |
Stockhead | OCC | 3 weeks ago |
Orthocell leaps closer to FDA approval after pivotal nerve-repair product study success
Orthocell US FDA 510(k) regulatory study of peripheral nerve-repair product Remplir meets all endpoints Company due to submit 510(k) application in December with US FDA approval expected in Q1 CY25 Study found use of Remplir results in hig... |
Stockhead | OCC | 3 weeks ago |
Health Check: No sign of frayed nerves as Orthocell girds for US approval
“Outstanding” pivotal trial results paves the way for Orthocell to seek US approval for its Remplir nerve wrap Percheron promises Duchenne trial results by Christmas Argent Biopharma says it’s not goodbye – or au revoir Orthocell (ASX:O... |
Stockhead | OCC | 3 weeks ago |
Orthocell clears milestone for US launch of Remplir
Orthocell (ASX:OCC), a Perth-based regenerative medicine company, has successfully completed a pivotal US FDA 510(k) regulatory study for its nerve repair product, Remplir. The study validated Remplir as safe and effective for use in the su... |
ShareCafe | OCC | 3 weeks ago |
Why this ASX healthcare share is soaring 26% on study findings
Orthocell Ltd (ASX: OCC) shares are starting the week with a very big bang. In morning trade, the ASX healthcare share is up 26% to a 52-week high of $1.02. Why is the ASX healthcare share soaring today? Investors have been fighting to get... |
Motley Fool | OCC | 3 weeks ago |
Breaking Out: Regenerative medicine play Orthocell’s run might just be getting started
Breaking Out is a technical analysis-fuelled, short ‘n’ sharp take on chart-busting ASX stocks. Each week, Steve Collette – head of Collette Capital in Melbourne – narrows in on something that’s caught his eye. Orthocell (ASX:OCC) Orthoce... |
Stockhead | OCC | 3 weeks ago |
ASX Winners and Losers Key Performers and Sector Trends Today
Highlights ASX 300 showcases top movers with significant percentage changes across sectors. Consumer Discretionary and Telecommunications drive market gains amid stable sentiment. ASX mining and energy stocks experience mixed outcomes... |
Kalkine Media | OCC | 3 weeks ago |
Web Travel Group Surges on TTV Growth, Pinnacle Declines After SPP Announcement
Highlights Web Travel Group WEB shares rise 13.48% following strong TTV growth. Pinnacle Investment Management PNI declines after announcing $25M SPP. ASX rebounds, with all sectors closing in positive territory. The Australian sh... |
Kalkine Media | OCC | 3 weeks ago |
Closing Bell: ASX up on broad rally; but City Chic tumbles heavily after trading update
ASX rises on rally across the board Israel and Hezbollah agree to 60-day ceasefire City Chic tumbles after downbeat update The Aussie share market enjoyed a solid ride on Wednesday, driven by a broad rally as optimism from Wall Street’s... |
Stockhead | OCC | 3 weeks ago |
Break it Down: Orthocell takes next leap into Singapore sales
Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Sarah Hughan tells all on Orthocell’s (ASX:OCC) medical device sales in Singapore on the appointment of an exclusive distributor. It... |
Stockhead | OCC | 3 weeks ago |
Orthocell announces Singapore distribution deal
Orthocell (ASX:OCC) has appointed Device Technologies Asia (DVT Asia) as the exclusive distributor of its nerve repair device, Remplir, in Singapore. This marks the product's first major international expansion beyond Australia and New Zeal... |
ShareCafe | OCC | 3 weeks ago |
Orthocell appoints distributor for nerve repair product Remplir in Singapore
Orthocell appoints Device Technologies Asia as exclusive distributor of nerve repair product Remplir in Singapore Device Technologies has been credited with driving rapid sales of Remplir in Australia and New Zealand Orthocell said market... |
Stockhead | OCC | 3 weeks ago |
Renerve all set to become only the second nerve-repair stock on the ASX
Nerve-repair company Renerve is set to make its ASX debut today Renerve is developing products for repair and replacement of damaged peripheral nerves It becomes only the second nerve-repair company on the ASX, after Orthocell When Rene... |
Stockhead | OCC | 3 weeks ago |
Long Shortz with Orthocell: No nerves as company enters US market
Stockhead’s Sarah Hughan sits down with Orthocell (ASX:OCC) chairman John Van Der Wielen to get the short end of the long story on the company’s latest news. The regenerative medicine company has appointed two US-based executives to drive t... |
Stockhead | OCC | 1 month ago |
Biocurious: No sweat as Botanix tackles the world’s third-biggest skin disorder
Botanix has FDA approval for its treatment for hyperhidrosis, or excessive sweating Sufferers have not had an effective treatment for the socially debilitating disorder Broker E&P Financial Group estimates revenues of close to $100 mil... |
Stockhead | OCC | 1 month ago |
October Health Winners: Uscom, Respiri lead sluggish sector, but ‘time in the market, not timing, is key’
ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th... |
Stockhead | OCC | 1 month ago |
Orthocell secures $17m to fund US entry
Orthocell (ASX:OCC) has secured $17m in a recent capital raising initiative, aimed at funding the US launch of its flagship Remplir device. The funds will also support expansion into Singapore, Southeast Asia, and Europe, and be allocated t... |
ShareCafe | OCC | 1 month ago |
Orthocell raising $17M in placement to fund US launch of Remplir
Orthocell (ASX:OCC) has announced its receipt of commitments for $17M in funding via placement to bankroll the US launch of Remplir. Remplir is a skin-like, collagen-based warp used in specific wound repairs with a view towards patient... |
themarketonline.com.au | OCC | 1 month ago |
Closing Bell: Telix, banks lift ASX; but Newmont and Fortescue trip over soaring costs
ASX ends very modestly lower after a mixed session Newmont and Fortescue shares drop on disappointing updates WiseTech continues its slide as investors start to grumble Aussie shares swung to a flattish close today after earlier losses... |
Stockhead | OCC | 1 month ago |
Orthocell brings in more heavy hitter investors in new $15 million-plus raising
The nerve-repair company’s shares have been on a tear after a series of positive regulatory and operating updates. |
The West | OCC | 1 month ago |
ASX200 Falls Amid Market Re-Evaluation as Health Care Leads Declines
Highlights ASX200 index falls 1.66% in its worst day in seven weeks. Health Care sector takes the largest hit, down 2.4%. Wisetech bounces back 2.84% after litigation settlement. The ASX200 experienced a significant drop of... |
Kalkine Media | OCC | 2 months ago |
ASX Market Close: Wisetech bounces back as Index takes a breather | October 22, 2024
The ASX200 closed down 1.66% at 8,205 points in its worst day in seven weeks. The local bourse shed some of the gains from recent weeks as investors took profits and re-evaluated their portfolios. Health Care suffered the biggest loss... |
themarketonline.com.au | OCC | 2 months ago |
ASX innovators reshaping traditional medical treatments
EBR has developed the WiSE Cardiac Resynchronization Therapy (CRT) system, the world’s first leadless pacing system for heart failure Trytamine Therapeutics is pioneering a precision approach to psychedelics, targeting precise drug blood l... |
Stockhead | OCC | 2 months ago |
Long Shortz with Orthocell: Gateway to Asia open with Singapore market entry
Stockhead’s Sarah Hughan sits down with Orthocell’s (ASX:OCC) CEO and MD Paul Anderson to get the short end of the long story on the company’s latest news. The company has received regulatory approval from the Health Sciences Authority in S... |
Stockhead | OCC | 2 months ago |
Biocurious: With Singaporean approval ticked off, Orthocell eyes the crucial US nerve-repair market
Singapore’s medical regulator this week approved Orthocell’s leading nerve-repair device Remplir Remplir shows great promise in restoring function for paraplegics and quadriplegics Orthocell estimates the potential global market at US$33... |
Stockhead | OCC | 2 months ago |
Orthocell gets approval in ‘gateway’ market of Singapore for nerve repair product
Shares in regenerative medicine company Orthocell soared after the company received regulatory approval for its nerve repair product in Singapore. |
The West | OCC | 2 months ago |
ASX200 Declines Amid Iron Ore Price Drop and China's Economic Shift
Highlights ASX200 closed down 0.35% at 8,176 points. Iron ore prices fell as China shifted focus from construction to consumer confidence. Health Care sector gained 0.75%, while Materials dropped 1.75%. The ASX200 index closed 0.3... |
Kalkine Media | OCC | 2 months ago |
ASX Market Close: Iron Ore falls after China stimulus disappoints investors | October 8, 2024
The ASX200 closed down 0.35% at 8,176 points. Iron ore prices fell from US$114/tn to US$108/tn in Singapore on news the Chinese government’s stimulus will focus more on boosting domestic spending. Instead of driving new construction,... |
themarketonline.com.au | OCC | 2 months ago |
Orthocell wins first international approval for nerve repair product
West Australia-based regenerative medicine play Orthocell (ASX: OCC) has received regulatory approval from the Health Sciences Authority in Singapore to commence sales of its nerve repair product, Remplir. It’s the first international ap... |
themarketonline.com.au | OCC | 2 months ago |
Orthocell secures regulatory approval to launch Remplir sales in Singapore
Orthocell gains regulatory approval from Singapore’s Health Sciences Authority for its nerve repair product Remplir It is the first major international approval for Remplir outside of Australia and New Zealand Orthocell said Singapore was... |
Stockhead | OCC | 2 months ago |
HEALTH CHECK: Lion City’s Orthocell approval provides a Singapore Sling-board to Asian markets
Orthocell wins Singaporean approval for its Remplir nerve-repair product Lumos wraps up $10 million whip-round amid surge of raisings in the sector ‘Nice tidy’ Cyclopharm eyes profitability from next year as US revenues grow It’s not th... |
Stockhead | OCC | 2 months ago |
Orthocell delivers second quarter of record revenue
Orthocell achieves a second consecutive quarter of record revenue, reporting $2.03m in Q1 FY25 Revenue is up 7.82% on $1.88m achieved in Q4 FY24, showing traction with growing sales of Striate+ and Remplir Company said FDA approval of Rem... |
Stockhead | OCC | 2 months ago |
Closing Bell: Arcadium soars 47pc as Rio makes move; retailers beg RBA to cut rates before Christmas
ASX rises as banking and tech sectors lead gains Arcadium Lithium surges on potential acquisition by Rio Tinto Retail groups urge Reserve Bank to cut rates ahead of holiday sales The ASX200 index rose by 0.7% on Monday though investors... |
Stockhead | OCC | 2 months ago |
Health Check: Long-suffering Mesoblast investors dare to dream
Mesoblast expects FDA stem cell drug approval by the first week of January ‘if not earlier’ FDA to Somnomed: ‘do you want the good news or bad news first?’ Neurotech mulls its US options after FDA’s orphan drug decision Orthocell says reve... |
Stockhead | OCC | 2 months ago |
September
Health Winners: EZZ and Althea lead upbeat sector sparked by Fed rate cut
Healthcare stocks are doing relatively well globally in 2024 The sector could see more recovery as Fed cuts rates How ASX biotechs performed in the month of September The S&P 500 Health Care Index, a key world benchmark for health... |
Stockhead | OCC | 2 months ago |
ASX health stocks capitalise on growing Southeast Asian market
Southeast Asia presents growth for ASX health stocks with rising aging population and growing middle class EZZ has started selling EAORON branded products in Vietnam and signed Australian Open sponsorship deal Recce has signed a MoU with... |
Stockhead | OCC | 2 months ago |
ASX Market Close: Banks lead Index to finish the week on a high | September 6, 2024
The ASX200 closed up 0.39% at 8,013 points. The bank stocks rallied leading the index higher, but Energy and mining stocks slumped in the wake of falling commodity prices. Financials was the best performing sector, up 1.45%, followed... |
themarketonline.com.au | OCC | 3 months ago |
WA biotech Orthocell marks first sales of dental bone repair product in $60m Canadian market
WA regenerative medicine company Orthocell has started selling its dental bone repair product in Canada — a market estimated to worth to be about $60 million. |
The West | OCC | 3 months ago |
ASX Market Update: CBA breaks record as banks lead Index higher | September 6, 2024
The ASX200 has been up around 0.5% at 8,025 points. Bank stocks have surged and dragged the market higher with the big 4 all outperforming and dragging the bourse higher. In commodities, the gold price is fetching more than US$2500 an... |
themarketonline.com.au | OCC | 3 months ago |
Break it Down: Orthocell smiles on key sales
Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, Fraser Palamara explains why the Canadian market is so important for Aussie pharmaceutical Orthocell. Tune in to get the latest. While Or... |
Stockhead | OCC | 3 months ago |
Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil
Orthocell (ASX:OCC) has confirmed it’s sold its first units of collagen-based bone repair product Striate+ in Canada through distro partner BioHorizons. The move effectively represents a further expansion for the company into another we... |
themarketonline.com.au | OCC | 3 months ago |